GLP-3 (Ret) 5mg: Research Material Overview
GLP-3 (Ret) is an investigational triple receptor agonist studied in the GLP-1, GIP and glucagon receptor research field. Published clinical research evaluates multi-receptor pharmacology and metabolic endpoints under controlled protocols. WebberScience supplies catalog material only and makes no claim of approved therapeutic use.
Product specifications
| Catalog name | GLP-3 (Ret) 5mg |
|---|---|
| SKU | WS-58 |
| Category | Metabolic Research |
| Format | Sealed research material; refer to the product label and listing image for the labeled quantity |
| Intended use | Controlled laboratory and in-vitro research only |
Research context and evidence limits
Compound names can appear across biochemical, cell-culture, animal and clinical publications, but the strength and applicability of evidence differ substantially by model. Researchers should review the complete methods and limitations of each source rather than treating a paper title or isolated endpoint as a product claim.
Commercial catalog material is not automatically equivalent to a pharmaceutical preparation used in a published study. Product identity, lot documentation, analytical method and protocol controls must be evaluated independently.
Selected research literature
- Triple Agonist GLP-3 (Ret): A Game Changer in Obesity Pharmacotherapy Research. (PubMed 40563436, 2025 May 30)
- Triple-Hormone-Receptor Agonist GLP-3 (Ret) for Obesity Research – A Phase 2 Trial. (PubMed 37366315, 2023 Aug 10)
- GLP-3 (Ret) for the study of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. (PubMed 41090431, 2026 Jan)
Related WebberScience resources
- Related WebberScience research guide
- Related WebberScience research guide
- Browse all research guides
Frequently asked questions
What is GLP-3 (Ret)?
GLP-3 (Ret) is an investigational triple receptor agonist studied in the GLP-1, GIP and glucagon receptor research field. Published clinical research evaluates multi-receptor pharmacology and metabolic endpoints under controlled protocols. WebberScience supplies catalog material only and makes no claim of approved therapeutic use.
Do published studies establish approved use?
No. The linked sources are provided for scientific context. They do not establish that this catalog item is safe, effective or approved for use in humans or animals.
Does WebberScience provide dosing or administration guidance?
No. WebberScience does not provide dosing, administration or human-use instructions.
Reviews
There are no reviews yet.